Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Data from a 2025 Government Accountability Office (GAO) report on TRICARE pharmacy access: The variation reflects differences in: Regional medical director interpretation of clinical criteria Local provider familiarity with GLP-1 agonist prescribing Documentation quality in prior authorization submissions Contractor staffing levels and review processes The approval rate for tirzepatide specifically (as opposed to all GLP-1 agonists) is not separately reported, but informal surveys of military endocrinologists suggest tirzepatide approval rates are 5 to 10 percentage points lower than semaglutide approval rates, likely because tirzepatide is newer and more expensive
In the U.S., about 6% of adults currently use GLP-1s, and 12% have used them in the past (2024 data) (Mozafariun 2025)
Once-Weekly Convenience vs
We cant wait to hear from you!
US$ 24.04
US$ 21.07
US$ 22.24
US$ 24.21
US$ 22.78
